재고 위치

New Jersey, USA
Czech Republic, EU
Mumbai, India

* 재고 가용성에 따라 다름

Documentation

MSDS 다운로드

샘플 COA 다운로드

포함 사항: HPLC, MASS/LC-MS, 1H NMR, FT-IR, 함량, 구조 규명 보고서(SER), 그리고 제품에 따라 추가 분석 데이터가 제공됩니다.

94703-34-1Amoxicillin Trimer Impurity

● Under Development

카탈로그 번호:	VL1970019
CAS 번호:	94703-34-1
분자식:	C48H54N9Na3O15S3 .
분자량:	1162.16

무엇을 도와드

RFQ 목록에 추가

에 대한 추가 정보 CAS 94703-34-1

모약물

Amoxicillin

IUPAC명

(2R,2’R,4S,4’S)-2,2′-((1R,4S,7R,10R)-1-amino-14-(((2S,5R,6R)-2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptan-6-yl)amino)-1,7,13-tris(4-hydroxyphenyl)-2,5,8,11,14-pentaoxo-3,6,9,12-tetraazatetradecane-4,10-diyl)bis(5,5-dimethylthiazolidine-4-carboxylic acid) Trisodium Salt

Pharmacopeial Synonyms

N/A

동의어

N/A

SMILES

O=C(N[C@H]1[C@@]2([H])SC(C)(C)[C@H](C([O-])=O)N2C1=O)C(C3=CC=C(O)C=C3)NC([C@H]([C@H]4SC(C)(C)[C@H](C([O-])=O)N4)NC([C@@H](C5=CC=C(O)C=C5)NC([C@@H]([C@H]6SC(C)(C)[C@H](C([O-])=O)N6)NC([C@H](N)C7=CC=C(O)C=C7)=O)=O)=O)=O.[Na+].[Na+].[Na+]

InChI

InChI=1S/C48H57N9O15S3.3Na/c1-46(2)31(43(67)68)55-39(73-46)28(52-34(61)25(49)19-7-13-22(58)14-8-19)37(64)50-26(20-9-15-23(59)16-10-20)35(62)53-29(40-56-32(44(69)70)47(3,4)74-40)38(65)51-27(21-11-17-24(60)18-12-21)36(63)54-30-41(66)57-33(45(71)72)48(5,6)75-42(30)57;;;/h7-18,25-33,39-40,42,55-56,58-60H,49H2,1-6H3,(H,50,64)(H,51,65)(H,52,61)(H,53,62)(H,54,63)(H,67,68)(H,69,70)(H,71,72);;;/q;3*+1/p-3/t25-,26-,27?,28+,29-,30-,31+,32+,33+,39-,40-,42-;;;/m1…/s1

설명

Amoxicillin Trimer Impurity (CAS 94703-34-1) is a multimeric degradation product formed by condensation and trimerization of amoxicillin under thermal, acidic or aqueous stress conditions, posing risks to potency and stability. Analytical characterization requires sensitive LC-MS and HPLC methods with validated limits of detection and quantification, supported by NMR and HRMS for structural confirmation. Control strategies include optimized synthesis and purification, stringent solvent selection, and in-process monitoring to limit formation. Accurate impurity profiling and specification setting in line with ICH guidelines enable risk assessment, batch release decisions and regulatory compliance for amoxicillin drug substance manufacture.

References

Huttner, A., et al. Oral Amoxicillin and Amoxicillinâ€“Clavulanic Acid: Properties, Indications and Usage.â€ Clinical Microbiology and Infection, vol. 26, no. 7, July 2020, pp. 871â€“879, 10.1016/j.cmi.2019.11.028.